Friday 16 October 2026
Export ALXO’s income statement to Excel — free account
ALX Oncology Holdings Inc.
ALXO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 73.5%, free cash flow grew 31.7% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.06
0.06
+6.00%
Follow ALXO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (80.65%) | (74.17%) | (145.70%) | (118.95%) |
+8 more TTM periods Free account |
|
| (63.16%) | (59.40%) | (98.34%) | (80.47%) | ||
ROIC |
(673.30%) | (291.68%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(62.78%) | (70.29%) | (371.50%) | (269.05%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.52) | (0.75) | (1.57) | (1.82) | |
Free Cash Flow |
(70.91) | (78.33) | (84.35) | (97.43) | |
Capital Expenditures |
(0.13) | (0.20) | (0.21) | (0.22) | |
| Other line items | |||||
Cash ROIC |
(24.96%) | (26.09%) | (104.76%) | (84.33%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(58.67) | (59.70) | (64.93) | (67.81) | |
Operating CF/Net income |
0.88 | 0.88 | 0.83 | 0.90 | |
Depreciation/Fixed assets |
(0.77) | 0.01 | (0.21) | (0.55) | |
Capex/Depreciation |
1.01 | (18.36) | 0.83 | 0.30 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.52) | (0.75) | (1.57) | (1.81) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates